SecBot SecBot
8-K ·Filed Jun 10, 2026

IOVA

IOVANCE BIOTHERAPEUTICS, INC.
BULLISH
Impact 7/10
Horizonweeks Processed5mo ago SEC0001104659-26-072408
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

The TGA approval opens a high-incidence melanoma market with significant unmet need. Watch for the number of authorized treatment centers in Australia and the pace of patient starts as leading indicators of Amtagvi revenue acceleration outside the US. The authorized share increase (150M new shares) may be used for future financing, so monitor equity raises.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$3.96
T+0 close · Jun 10, 2026 · via day close
Latest settled
+121.97%
T+60 · $8.79
Vs SPY
+117.57%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 11 $3.96entry
  2. T+1 · 5mo ago +3.03%α +2.49% · $4.08
  3. T+5 · 5mo ago −0.76%α −1.19% · $3.93
  4. T+20 · 4mo ago +10.35%α +8.46% · $4.37
  5. T+60 · 2mo ago +121.97%α +117.57% · $8.79
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Iovance Biotherapeutics received marketing authorization from the Australian TGA for Amtagvi (lifileucel) for advanced melanoma, marking its third regulatory approval and expanding into a market with the highest global melanoma incidence. Shareholders also approved an increase in authorized common shares from 500M to 650M, providing flexibility for future capital needs.

Key Facts

  • Received TGA (Australia) marketing authorization for Amtagvi in advanced melanoma, the company's third global approval
  • Australia has the highest rate of melanoma globally with ~17,000 new cases annually
  • Shareholders approved increasing authorized common shares from 500M to 650M
  • Company is authorizing its first Australian treatment center and advancing expansion strategy
  • All six director nominees were elected, and all seven shareholder proposals passed

Financial Impact

No specific revenue or financial figures disclosed in the filing for the Australian market. The authorized share increase from 500M to 650M provides dilution capacity but no shares were issued in this filing.

regulatory approvalsauthorized share count

Risk Factors

  • Commercial execution risk in a new geographic market
  • Dilution risk from 150M additional authorized shares that could be issued
  • Revenue recognition and reimbursement timelines in Australia remain uncertain
  • Competing PD-1 and targeted therapies are standard of care

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
81% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-072408
Document: tm2613648d1_ex99-1.htm0001104659-26-072408
Document: 0001104659-26-072408-index-headers.html0001104659-26-072408
Document: 0001104659-26-072408-index.html0001104659-26-072408
Document: 0001104659-26-072408.txt0001104659-26-072408

Track record

21 reports on IOVA

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +40.10% at T+20 after the Aug 6, 2026 report. 4 of 6 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $8.08 Now $7.55 −6.56% settles Dec 9
  2. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $8.04 Now $7.55 −6.09% settles Dec 7
  3. Nov 5, 202611d ago 8-K Bullish 6/10 Entry $7.74 Now $7.55 −2.45% settles Dec 4
  4. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $8.70 Now $7.55 −13.22% settles Dec 3
  5. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $8.48 Now $7.55 −10.97% settles Nov 30
  6. Oct 28, 202619d ago Press Release Bullish 7/10 Entry $9.56 Now $7.55 −21.03% settles Nov 27
  7. Oct 5, 20266w ago 8-K Neutral 4/10 Entry $12.96 to $8.65 Now $7.55 −41.74% ▼ −33.25% −30.34% vs SPY
  8. Oct 2, 20266w ago 3 Neutral 2/10 Entry $14.15 to $7.93 Now $7.55 −46.64% ▼ −43.99% −41.42% vs SPY
  9. Sep 29, 20266w ago 8-K Bullish 6/10 Entry $14.45 to $14.58 Now $7.55 −47.75% ▲ +0.90% +0.19% vs SPY
  10. Aug 21, 202612w ago Press Release Neutral 2/10 Entry $8.06 to $10.64 Now $7.55 −6.33% ▲ +32.01% +30.70% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 5m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 10, 2026